Compare CABA & PESI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | PESI |
|---|---|---|
| Founded | 2017 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Environmental Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 243.9M |
| IPO Year | 2019 | 1996 |
| Metric | CABA | PESI |
|---|---|---|
| Price | $3.63 | $13.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $14.57 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 147.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $60,030,000.00 |
| Revenue This Year | N/A | $9.91 |
| Revenue Next Year | N/A | $62.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $6.25 |
| 52 Week High | $3.78 | $16.50 |
| Indicator | CABA | PESI |
|---|---|---|
| Relative Strength Index (RSI) | 71.51 | 33.60 |
| Support Level | $2.11 | $12.24 |
| Resistance Level | N/A | $14.82 |
| Average True Range (ATR) | 0.26 | 0.74 |
| MACD | 0.07 | -0.31 |
| Stochastic Oscillator | 98.94 | 5.94 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.